spacer spacer

Papers

SCNP Platform Technology

Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts.
Cesano A, Rosen DB, O'Meara P, Putta S, Gayko U, Spellmeyer DC, Cripe LD, Sun Z, Uno H, Litzow MR, Tallman MS, and Paietta E.
Cytometry Part B 2012;82B:158-172.

Beyond sequencing: new diagnostic tests turn to pathways.
Garber, K.
JNCI J Natl Cancer Inst. 2011;103(4):290-2.

Mapping normal and cancer cell signalling networks: towards single-cell proteomics.
Irish JM, Kotech N, and Nolan GP.
Nature Rev Cancer. 2006;6:146-55.

Single cell profiling of potentiated phospho-protein networks in cancer cells.
Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud Ø, Gjertsen BT, and Nolan GP.
Cell. 2004;118:217-28.

Drug Development

Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.
Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, and Jessup JM.
Clin Cancer Res 2012;18:1515-1523.

Single-Cell Network Profiling (SCNP) by flow cytometry in autoimmune disease.
Covey TM, Cesano A, and Parkinson DR.
Autoimmunity. 2010;43:1-10.

Single Cell Network Profiling (SCNP): mapping drug and target interactions.
Covey TM, Putta S, and Cesano A.
Assay Drug Dev Technol. 2010;8:321-43.

Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling.
Krutzik PO and Nolan GP.
Nat Methods. 2006;3:361-36.

Hematologic Malignancies

Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.
Cesano A, Putta S, Rosen DB, Cohen AC, Gayko U, Mathi K, Woronics J, Hawtin RE, Cripe L, Sun Z, Tallman MS, and Paietta E.
PLOS One 2013;8(2):e56714.

AKT signaling as a novel factor associated with in-vitro resistance of human AML to gemtuzumab ozogamicin.
Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, and Walter RB.
PLoS ONE 2013;8(1):e53518.

Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.
Cesano A, Perbellini O, Evensen E, Chu CC, Cioffi F, Ptacek J, Damle RN, Chignola R, Cordeiro J, Yan X, Hawtin RE, Nichele I, Ware JR, Cavallini C, Lovato O, Zaanotti R, Rai KR, Chiorazzi N, Pizzolo G, and Scupoli MT.
Haematologica 2012;97:ePub ahead of print.

Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.
Rosen DB, Cordeiro JA, Cohen A, Lacayo N, Hogge D, Hawtin RE, and Cesano A.
Leuk Res 2012;36:900-904.

Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.
Palazzo AL, Evensen E, Huang Y-W, Cesano A, Nolan GP, and Fantl WJ.
PLoS One 2011;6(10):e24592. doi:10.1371/journal.pone.0024592.

Signaling changes in the stem cell factor–AKT-S6 pathway in diagnostic AML samples.
Kornblau SM, Covey T, Putta S, Cohen A, Woronicz J, Fantl WJ, Gayko U, and Cesano A.
Blood Cancer Journal. (2011) 1, e3; doi:10.1038/bcj.2010.2.

Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).
Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, Putta S, Woronicz J, Evensen E, Fantl WJ, and Cesano A.
Plos One. 2010;5(10):e13543.

Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications.
Covey TM and Cesano A.
Best Pract Res Clin Haematol. 2010;23(3):319-31.

Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3Kinase response profiles in human acute myelogenous leukemia.
Rosen DB, Putta S, Covey T, Huang Y-W, Nolan GP, Cesano A, Minden MD, and Fantl WJ.
Plos One. 2010;5(8):e12405.

Dynamic single cell network profiles in AML are associated with patient response to standard induction therapy.
Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, and Cesano A.
Clin Cancer Res. 2010;16:3721-33.

Insights into acute myeloid leukemia via single cell network profiling.
Kornblau A, Minden SM, Hogge D, Cohen A, and Cesano A.
CLi. 2010;34:12-5.

Personalized Medicine

Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR, Johnson BE, and Sledge GW.
Clin Cancer Res 2012;18:619-624.

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?
Fojo T and Parkinson DR.
Clin Cancer Res 2010;16:5972-5980.

The revolution is here - are you ready?
Parkinson DR.
EJHP Practice. 2010;16:12.

Patient-specific classifications of human malignant disease.
Parkinson DR and Cesano A.
Curr Opin Mol Ther. 2009;11:252-9.

Educating for personalized medicine: a perspective from oncology.
Parkinson DR and Ziegler J.
Clinical pharmacology And Therapeutics. July 2009;86(1):23-25.

What's wrong with drug screening today.
Nolan GP.
Nat Chem Biol. 2007;3:187-191.

Immune System Monitoring

Racial differences in B cell receptor signaling pathway activation.
Longo DM, Louie B, Mathi K, Pos Z, Wang E, Hawtin RE, Marincola FM, and Cesano A.
J Transl Med 2012;10:113.

Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation.
Longo DM, Louie B, Putta S, Evensen E, Ptacek J, Cordeiro J, Wang E, Pos Z, Hawtin RE, Marincola F, and Cesano A.
J Immunol; Prepublished online 13 January 2012; doi:10.4049/jimmunol.1102514.

Other

Single Cell Network Profiling Assay in Bladder Cancer.
Covey TM, Vira MA, Westfall M, Gulrajani M, Cholankeril M, Okhunov Z, Levey H, Marimpietri C, Hawtin R, Fields SZ, and Cesano A.
Cytometry Part A 2013; 83(1).

Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
Leung M, Rosen D, Fields S, Cesano A, and Budman DR.
Mol Med 2011;17:854-862.